American Society of Hematology

Figure 3

Tumor-to-normal organ ratios of retained radioactivity following targeting of human T-NHL xenografts with 131I-BC8 (anti-CD45) and I-125-BHV-1 (control). Tumor-to-normal organ ratios of percentage injected radioiodine/g tissue of 131I-BC8 (anti-CD45, ■) and 125I-BHV-1 (control, ) in mice with CCRF-CEM (A,B) and Karpas 299 (C,D) xenografts after 24 and 48 hours.

Tumor-to-normal organ ratios of retained radioactivity following targeting of human T-NHL xenografts with ¹³¹I-BC8 (anti-CD45) and I-125-BHV-1 (control). Tumor-to-normal organ ratios of percentage injected radioiodine/g tissue of ¹³¹I-BC8 (anti-CD45, ■) and ¹²⁵I-BHV-1 (control, ) in mice with CCRF-CEM (A,B) and Karpas 299 (C,D) xenografts after 24 and 48 hours.

This Feature Is Available To Subscribers Only